Antenatal exposure to nonsteroidal anti‐inflammatory drugs and risk of neonatal hypertension

• DOI: 10.1111/jch.13354
• Publication Date: 2018-07-27T11:40:38Z
• Authors: Mounira Habli; Corey C. Clifford; Tammy M. Brady; Zahidee Rodriguez; Michaela Eschenba...; Malcolm Wu; Emily DeFranco; James Gresh; Beena D. Kamath‐R...
• Keywords: Bronchopulmonary Dysplasia; Gestational hypertension; Umbilical artery; Tocolytic agent

Nonsteroidal anti‐inflammatory drugs ( NSAID s) are used as tocolytics, which medications that suppress uterine contractions for preterm birth prevention. Their effect on cerebral/systemic vascular beds poses the question of whether antenatal exposure is associated with neonatal hypertension. We performed a retrospective case‐control study in tertiary intensive care unit, including 40 hypertension cases (hospitalized neonates ≥ 35 weeks systolic BP > 100 mm Hg three consecutive days) compared to 134 controls matched by gestational age at delivery, plurality, and delivery date. Cases were exposure, other common maternal/neonatal characteristics complications. Multivariable logistic regression was estimate odds among those prenatal s versus without exposure. Newborns had lower increased incidence complications, respiratory distress syndrome, bronchopulmonary dysplasia, surfactant administration, longer duration ventilation, history umbilical artery catheterization. Days indomethacin positively greater OR 1.17 [1.00 1.38], P = 0.055), even after adjustment factors less likely have been exposed calcium channel blockers tocolytic. The results our suggest an association between nonsteroidal Furthermore, data blocker may protect against development Future multicenter studies needed understand risks tocolytics subsequent consequences infants.